← Back to Search

Exercise for Parkinson's Disease

Led By Marc Roig, Ph.D.
Research Sponsored by McGill University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks (post-intervention) and 8 weeks (follow-up)
Awards & highlights


This trial will look at how exercise affects sleep in people with Parkinson's and its effect on quality of life. 4 groups of participants will exercise 3x/week for 12 weeks and be assessed at baseline and post-intervention.

Who is the study for?
This trial is for people with mild to moderate Parkinson's Disease who have poor sleep quality. They must be on a stable medication dose and not have severe cognitive or mental health issues, untreated sleep apnea, osteoporosis, or other neurological conditions. They shouldn't already be very active or in another exercise/drug study.Check my eligibility
What is being tested?
The study tests how cardiovascular training (CT), resistance training (RT), and multimodal training (MT) affect sleep and life quality in Parkinson's patients over 12 weeks. Participants will train three times a week and are compared to a control group on a waiting list.See study design
What are the potential side effects?
Exercise programs may cause muscle soreness, fatigue, joint pain, or increase the risk of falls especially if balance is affected by Parkinson’s disease. However, these side effects vary from person to person.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks (post-intervention) and 8 weeks (follow-up)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks (post-intervention) and 8 weeks (follow-up) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Changes in objective sleep quality
Changes in sleep architectures
Changes in subjective sleep quality
Secondary outcome measures
Changes in Quality of Life Scale
Changes in cognitive function
Changes in fatigue
+2 more
Other outcome measures
Cardiorespiratory fitness
Inflammatory biomarkers

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Group I: Resistance training (RT)Experimental Treatment1 Intervention
Resistance training (RT) intensity will be estimated using the percentage of one-maximal repetition (1-RM) defined as the maximal weight liftable for ten maximal repetitions with proper form. The program will include five exercises (leg press, lat machine, leg extension, leg curl, bench press) and will start at high-volume low intensity. RT will follow a periodization to reach high-intensity low-volume at the end of the intervention (week 12). The training sessions will start and end with five-minute of warm-up and cool-down, which will include exercise on a recumbent stepper and stretching, respectively. RT's sessions will last approximately 45 minutes (40 to 50 minutes) and will be interspersed with 48 hours of recovery.
Group II: Multimodal training (MT)Experimental Treatment1 Intervention
Multimodal training (MT) will combine cardiovascular and resistance training interventions using the modalities described previously, but each component will be shortened to match the overall training duration (i.e., volume) among groups. The first part of each training session will always include three resistance exercises, which will be followed by 15-20 minutes of cardiovascular training performed on the total body recumbent stepper. Periodization will follow the same progression previously described for cardiovascular and resistance training, respectively, reaching vigorous intensity towards the end of the training period. Training sessions will include a five-minute warm-up and cool-down on the total body recumbent stepper. MT's sessions will approximately last 45 minutes (40 to 50 minutes) and will be interspersed with 48 hours of recovery.
Group III: Cardiovascular training (CT)Experimental Treatment1 Intervention
Cardiovascular training (CT) will be performed on a recumbent stepper. CT will start at low intensity, and, through a linear progression, will reach vigorous intensity; then, this intensity will be maintained until the end of the training period. Each session will include five minutes of warm-up and cool-down performed at the beginning and at the end of the training, respectively. Furthermore, five minutes of stretching will be performed after the cool-down. CT's sessions will last approximately 45 minutes (30 to 50 minutes) and will be interspersed with 48 hours of recovery.
Group IV: Control condition (CON; waiting list)Active Control1 Intervention
The control condition (CON; waiting list) will receive no intervention (i.e., exercise) but usual care. Participants in the CON will be required to go about their normal life, maintaining their current physical activity levels until the end of the study. Then, they will be offered to join one of the training programs/condition.
First Studied
Drug Approval Stage
How many patients have taken this drug
Resistance training (RT)
Completed Phase 3

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Parkinson's Disease (PD) include pharmacologic therapies like levodopa, dopamine agonists, and MAO-B inhibitors, which work by replenishing or mimicking dopamine to alleviate motor symptoms. Nonpharmacologic treatments, such as cardiovascular, resistance, and multimodal exercise, are also essential. These exercises improve sleep quality and architecture, which is crucial for PD patients as poor sleep can worsen both motor and nonmotor symptoms, thereby enhancing overall quality of life. Additionally, exercise promotes neuroplasticity, potentially slowing the progression of the disease.
Current Management and Emerging Therapies in Multiple System Atrophy.

Find a Location

Who is running the clinical trial?

Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,354 Previous Clinical Trials
26,460,369 Total Patients Enrolled
The Memory LabUNKNOWN
McGill UniversityLead Sponsor
400 Previous Clinical Trials
1,000,044 Total Patients Enrolled

Media Library

Cardiovascular training (CT) Clinical Trial Eligibility Overview. Trial Name: NCT05644327 — N/A
Parkinson's Disease Research Study Groups: Multimodal training (MT), Cardiovascular training (CT), Control condition (CON; waiting list), Resistance training (RT)
Parkinson's Disease Clinical Trial 2023: Cardiovascular training (CT) Highlights & Side Effects. Trial Name: NCT05644327 — N/A
Cardiovascular training (CT) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05644327 — N/A
~67 spots leftby Dec 2026